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Background: Refined therapy has helped to improve survival rates in rhabdoid tumors
(RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains
dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated
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rhabdoid tumor of the kidney; SD, stable disease; TTP, time to progression.
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in the management of hematologic malignancies in adults, safety in children has also
been demonstrated repeatedly.
Materials and methods: A retrospective series of patients who received decitabine
upon relapse or progression following therapy according to the EU-RHAB regimen is
presented. Due to the retrospective nature of analyses, response was defined as mea-
surable regression of at least one lesion on imaging. 850k methylation profiling was
donewhenever tumor tissue was available.
Results: A total of 22 patients with RT of any anatomical localization were included.
Most patients (19/22) presented with metastases. All received low-dose decitabine
with or preceding conventional chemotherapy. Patients received amedian of two (1-6)
courses of decitabine; 27.3% (6/22) demonstrated a radiological response. Molecular
analyses revealed increased methylation levels in tumors from responders. No exces-
sive toxicitywas observed. Clinical benefits for responders included eligibility for early
phase trials or local therapy. Responders showed prolonged time to progression and
overall survival. Due to small sample size, statistical correction for survivorship bias
demonstrated no significant effect on survival for responders.
Conclusions: Patients with RT demonstrate promising signs of antitumor activity after
multiagent relapse therapy including decitabine. Analyses of methylation data suggest
a specific effect on an epigenetic level. We propose to consider decitabine and other
epigenetic drugs as candidates for further clinical investigations in RT.
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1 INTRODUCTION
Rhabdoid tumors (RT) are aggressive malignancies affecting very
young children. The entity comprises tumors of the central nervous
system (ATRT) as well as extracranial malignant rhabdoid tumors
(eMRT) of soft-tissue and rhabdoid tumors of the kidney (RTK). RT are
characterized by genomic alterations in SMARCB1 or rarely, SMARCA4;
25%-35% of all patients carry a germ line mutation (GLM).1–4 Apart
from surgical resection and conventional chemotherapy, radiother-
apy, and high-dose chemotherapy (HDCT) have been established as
elements of multimodal therapy.5–9 For patients nonresponsive to
first-line therapy or who experience relapse, options are scarce and
prognosis is dismal. In a recent analysis of 100 patients with eMRT,
only 11.1% of patients with refractory or chemoresistant disease
(analyzed within four months from diagnosis), and 26.6% with early
relapse (analyzed at 12 months from diagnosis) survived five years
following diagnosis.10 Long-term survival in patients with refractory
or relapsed ATRT was only 14% and 5%, respectively, in a cohort of
143 patients.11 Analysis of large ATRT and eMRT collectives recently
discovered significant differences on an epigenetic level.12–15 Of
the three subgroups of ATRT reported by Johann et al., two (ATRT-
TYR and -SHH) demonstrate global hypermethylation. Consistently,
we sought to test the demethylating ability and potential clinical
benefit of low-dose decitabine (maximum of 20 mg per m2 body
surface area or 0.7 mg per kg bodyweight per day) for relapsed or
refractory RT.
Decitabine, originally developed as a cytotoxic agent, exerts epige-
netic effects especially at lower doses and has activity in the therapy of
malignancies with known hypermethylated genomes (e.g., myelodys-
plastic syndrome, acute myeloid leukemia (AML)).16,17 Safe use of the
drug in children also in combination with conventional cytostatics has
repeatedly been documented.18–21 Decitabine has been proven to
penetrate the blood-brain barrier.22
Encouraged by these data, decitabine was used in individual treat-
ment attempts for relapsed or refractory RT. Here we report a case
series of such patients and evaluate possible clinical benefits of
decitabine as an adjunct to conventional chemotherapy.
2 MATERIALS AND METHODS
2.1 Patients
We included patients enrolled into the EU-RHAB registry who demon-
strated relapse or progression on therapy and who had received at
least one course of decitabine. Patients were from the Czech Republic,
Denmark, Germany, Hungary, and Portugal. All patients had been
treated according to the EU-RHAB consensus recommendations
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(www.rhabdoid.de).23 EU-RHAB is an international registry for RT of
all anatomical locations, collecting data from primary and relapsed
or refractory cases.23 To better understand individual approaches
toward relapsed or refractory patients, we analyzed individual strate-
gies for affected patients (December 2015 to March 2019). Two
eligible patients were excluded due to incomplete data. Diagnoses
had been confirmed by INI-1 negativity (proving SMARCB1-deficiency)
employing WHO criteria in all patients. We did not observe any
SMARCA4-negative case. We retrieved basic clinical and treatment
information from the EU-RHAB database. Additional data were
retrospectively collected from treating institutions by case report
forms. Missing data were obtained by personal contact with treating
institutions (mail and structured telephone interviews).
2.2 Ethical considerations
The EU-RHAB consortium has received continuous ethical approval
for more than 10 years (Registry: ID 2009-532-f-S, latest amendment
12/2016; Relapse/Progression: ID 2018-302-f-S). The decision for an
off-label attempt of decitabine was made by the treating physicians
at the respective institutions following expert counseling by the prin-
cipal investigator of the EU-RHAB registry. Recommendations always
prioritized participation in clinical trials, whenever available. It also
considered the results of analyses from molecular tumor boards such
as INFORM.24 Patients and/or legal guardians (depending on age)
provided informed consent following disclosure of the experimental
nature of treatment and information on potential risks and benefits.
The counseling process as such and collection of pertinent data were
approved by the ethics committee of the LMU München, Project-Nr.
19-269.
2.3 Assessments
Clinical assessments and time points for imaging did not follow a stan-
dardized protocol as patients were treated individually and at dif-
ferent time points in relation to other therapeutic elements. Toxicity
was either reported according to common toxicity criteria (CTC) or
extracted from written reports. For statistical purposes, patients were
categorized as having experienced “relevant toxicity” or not, with rel-
evant being defined as grade 4 toxicity according to CTC or any other
event unexpected or requiring prolonged hospitalization.
Primary distinction into responders and non-responders was based
on imaging and accompanying documentation of the clinical course
provided by the treating institution. All imaging was evaluated by local
radiologists followed by review at the reference radiology institution
of the EU-RHAB consortium (Department of Diagnostic and Interven-
tional Radiology, University Medical Center Augsburg). Response to
therapy was defined as objective, measurable regression of at least
one lesion on magnetic resonance (n = 21) or computer tomography
(n = 1) imaging. Response status was not necessarily concordant with
the response assessment as defined in the EU-RHAB protocol. Stan-
dardized criteria for response assessment such as RANO or RECIST
could unfortunately not be applied due to a lack of uniform imaging
protocols in the retrospective data set and the exploratory approach
of this work.
2.4 Statistical analysis
IBM SPSS Statistics for Windows, version 24.0 and SAS, version 9.4
for Windows were used for survival analysis. Survival was measured
from the first dayof decitabine treatment. Kaplan-Meier analyseswere
made for time to progression (TTP) and overall survival (OS). The effect
of decitabine treatment on TTP and OS was evaluated by Cox regres-
sion with a time-dependent response indicator. Results were deemed
significant at p ≤ 0.05. For the statistical assessment of responders
among the molecular subgroups, a chi-square test was performed (R,
v.3.6.2).
2.5 Designation of molecular subgroups
Data on methylation profiles of tumors were either analyzed by 850k
methylation arrays or IDATs from previous analyses were retrieved. To
allocate tumors to specific DNA methylation subgroups, we used the
most recent version of theHeidelbergmethylation array classifier.12,25
In addition, tSNE analysis was performed as an orthogonal validation
of the random-forest–based classification results to confirm subgroup
allocations. As eMRT almost exclusively cluster with the ATRT-
MYC subgroup, patients with eMRT were excluded from subgroup
allocation.
3 RESULTS
A total of 22 patients were included. Rescue modalities were applied
according to individual circumstances, and included surgery, high-dose
chemotherapy, and radiotherapy. Demographics, disease and treat-
ment characteristics are summarized in Table 1. Following first-line
therapy, 10/22 (45.5%) children had achieved a complete remission but
subsequently relapsed; n = 12/22 (54.5%) did not achieve a complete
remission and were in progression at the time of decision for salvage
treatment. Different individual treatment concepts were initiated
depending on clinical variables and availability of molecular informa-
tion. Localized lesions were submitted to surgery or radiotherapy in
4/22. In 2/22 other innovative treatment regimens (n = 1 metronomic
therapy according to MEMMAT, n = 1 paclitaxel, carboplatin and
melphalan) were initiated, but either therapy was stopped due to rapid
progression. For the remaining 16 patients, use of decitabine was the
first treatment approach deviating from conventional chemotherapy
approaches such as the EU-RHAB regimen. Decitabine was adminis-
tered preceding conventional chemotherapy (Figure 1a). An example
of an often-used standard treatment regimen is provided in Figure 1b.
In specific cases, duration or doses were adjusted individually (for
further details, see Supporting Information Table S1).
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TABLE 1 Patient characteristics and prior treatment
n %
Total number 22
Diagnosis ATRT 12 54
Methylation subgroup SHH 8 66
(ATRT) SHH+ TYR 1 8
MYC 1 8




GLM No 15 68
Yes 6 27
Not tested 1 4




Age group <1 years 5 22
1-4 years 12 54
5-9 years 3 13
>9 years 2 9










Abbreviations: ATRT, atypical teratoid rhabdoid tumor; eMRT, extracranial malignant rhabdoid tumor; GLM, germ line mutation; M+, tumor dissemination
(solid metastasis, meningeosis, tumor cells in liquor); M−, no dissemination; RTK, rhabdoid tumor of the kidney.
a Methylation data available for two eMRT, one RTK, and one RTK in patient with synchronous tumor. All clusteredwithMYC.
b Age at first decitabine treatment.
3.1 Decitabine elicits antitumor activity in
patients with relapsed and progressive RT
To assess the effects of therapy enhancement employing decitabine,
the proportion of patients who showed signs of antitumor activity was
analyzed. In 6/22 (27.3%), a radiological response as defined abovewas
noted. Of the remaining patients, 4/22 (18.2%) did not demonstrate
any evaluable lesions at the time of decitabine treatment due to prior
local treatment and n = 12/22 (54.5%) revealed no response. Notably,
among non-responders, one patient presented with stable disease
and in two more patients a clinical response was reported, which
was not visible on imaging (improvement in neurological status in an
ATRT or regression of palpable mass in a superficial soft-tissue eMRT).
Characteristics of responders in comparison to non-responders and
those with non-evaluable disease are listed in Table 2. Responses
included decrease in primary tumor size and regression of solid metas-
tases or meningeosis (see Figure 2 for exemplary imaging and Table 3
for characterization of the radiological findings). Patients received
decitabine until scheduled completion (n = 4), progression on therapy
(n = 15), or when excessive hematologic toxicity occurred (n = 1). One
patient was moved to local therapy and subsequently enrolled into
a phase I trial (NCT02601937) without signs of progression (patient
7, see case reports), one patient stopped treatment due to parental
decision.
Following treatment with decitabine, 8/22 patients received no fur-
ther tumor-directed therapydue toprogressionor death. Four patients
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TABLE 2 Characteristics of responders, non-responders, and patients not evaluable for a response
Responder Non-responder Not evaluable
n % n % n %
Total number 6 100 12 100 4 100
Diagnosis
ATRT 4 67 7 58 1 25
eMRT 2 33 3 25 3 75
RTK – 1 8 –
Synchronous – 1 8 –
GLM
No 4 67 7 58 4 100
Yes 2 33 4 33 –
Not tested 1 8 –
Methylation subgroup
SHH 4 67 3 25 1 25
SHH+ TYR – 1 8 –
MYC – 3 25 2 50
Not tested 2 33 5 42 1 25
Sex
Male 3 50 6 50 4 100
Female 3 50 6 50 –
Age group
< 1 year 1 17 4 33 –
1-4 years 4 67 6 50 2 50
5-9 years 1 17 1 8 1 25
> 9 years – 1 8 1 25
Metastasis at time of event 6 100 11 92 2 50
Type of event
Progression 3 50 4 33 –
Relapse 3 50 8 67 4 100
Abbreviations: ATRT, atypical teratoid rhabdoid tumor; eMRT, extracranial malignant rhabdoid tumor; GLM, germ line mutation; RTK, rhabdoid tumor of the
kidney.
received palliative chemotherapy, 10were subjected to another exper-
imental therapy approach with a curative intent. Strategies included
tazemetostat (NCT02601937) (n = 3), the RIST regimen, MEMMAT
(NCT01356290 - no trial enrollment due to trial not open in coun-
try), metronomic chemotherapy according to Kieran et al., azacytidine,
arsenic trioxide or TEMIRI.26–29 One patient underwent HDCT with
subsequent autologous stem cell transplant. In addition, five patients
received radiotherapy and one had surgery.
3.2 Prolongation of TTP and EFS following
decitabine
All but one patient (95.5%) had progressive disease at some point, and
19/22 (86.4%) have died. One patient, who was among the patients
without evaluable lesions and received decitabine as part of adjuvant
chemotherapy after local therapy, was alive in complete remission (CR)
24months later. Twoothers are alivewith disease: onewas undergoing
metronomic chemotherapy, and the otherwas in palliative care atmost
recent follow-up.
Median TTP for all patients was 7.6 weeks, and median OS for all
patients 26.3 weeks. On Kaplan-Meier analyses, responders showed
prolonged TTP and OS in comparison with non-responders (12 weeks
vs. 3 weeks; 40 weeks vs. 15 weeks, respectively). Following statistical
adjustment for survivorship bias, responses were not significant (TTP:
P ≥ 0.05; hazard ratio (HR) = 0.64; OS: P≥ 0.05, HR = 1.11 for com-
parison between responders and nonresponders). Patients without
evaluable disease had a superior absolute TTP and OS (16 weeks;
45 weeks) but no significant survival benefit in comparison with
responders (TTP: P≥ 0.05; HR= 0.38; OS: P≥ 0.05, HR= 0.22).
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TABLE 3 Characteristics of radiological findings in responders
Patient Description of tumor Description of response
7 ATRTwith the primary tumor in the right frontal
lobe, multiple smaller metastases, mostly in
the cerebellum.
Metastatic lesions are of smooth, cystic
formation, isodense to cerebrospinal fluid, and
show no contrast agent uptake.
Primary tumor same size as in the first study.
Size regression of the biggest metastatic lesion in the left
cerebellar hemisphere from 8× 9× 8mm to
4× 3× 4mm.MRI signal unchanged to previous
imaging.
On the left temporopolar regionmultiple, aggregated
smaller lesion with a total size of 5× 6× 4mmon
previous imaging cannot be found in the second study.
Suspicious new lesion at the left tentorium, later identified
as newmetastasis.
Due to the new lesion classified as progressive disease
10 Spinal relapse of ATRTwithmultiple
disseminated nodules.
Most prominent two nodules are the biggest one
at LWK2/3 and a smaller one at BWK9.
Both are intraspinal, hypointense to
muscle/myelon, show contrast agent uptake
and have slightly irregular margins.
Overall reduction of the intraspinal tumormass.
The biggest metastatic nodule is not detectable in the
second study, but has been biopsied in between studies.
The smaller nodule, that due to the identical signaling is
definitely a metastasis, is also not detectable anymore
11 Hepatic eMRTwith peritoneal carcinosis and
lungmetastasis.
Sizemeasurement is difficult due to
dissemination. Thewhole liver is tumorus. In
the left hepatic lobe, an oval, polylobulated,
partly cystic, partly necrotic tumor nodule can
be circumscribed andmeasured.
Mixed response with ameasurable size reduction of the
primary tumor but further growth of metastasis.
Size regression of the circumscribable tumor nodule from
4.2× 5.5 to 3.3× 3.5 cm. Simultaneously definite size
increase of extra-hepatic tumormass.
Due to the significant growth of the extra-hepatic tumor
mass classified as progressive disease
14 Leptomeningeal dissemination of ATRTwith
T2-hypointense, noncontrast agent uptaking
lesions, that partially surround themyelon
along the whole spinal axis.
Measurable regression of intraspinal metastasis along the
cervical and lumbosacral spinal canal. Exemplary is a
size decrease of tumormaterial in the sacral dura sac
from 1.1× 0.4 cm to 0.3× 0.3 cm (height× depth)
Persistence of intracranial leptomeningeal dissemination
16 Relapse of a completely resected hepatic eMRT
with diffusemetastasis in the left hemithorax
most likely originating from the pleura.
Overall regression of the pleural metastatic tumormass
documented in two CT scans of the lung.
1. Scan: Decreasing apical pleural thickening; the larger
solid areas basal in the left basal pleura/lung are difficult
to assess but are estimatedwith size regression.
2. Scan: Further regression of the tumor changes in the left
thoracic half, the basal portion of the tumor has a
transverse diameter of about 4.5 cm against the
previous 5.5 cm
22 Infratentorial ATRTwith progressive spinal
meningeosis.
Clear volume regression of spinal meningeosis> 50%
3.3 Decitabine-enhanced therapy is well
tolerated
No treatment-related deaths were reported; one patient termi-
nated treatment due to severe hematologic toxicity. A total of
10 patients (45.5%) experienced 13 relevant toxicities, including
hematologic toxicity (n = 6), as well as infections (n = 4), one
case of mild veno-occlusive disease and one patient suffering from
a disturbed sleep-wake cycle. One patient suffered from severe
hyponatremia with respiratory insufficiency and seizures. This was
attributed to administration of intraventricular methotrexate (0.5mg);
a following course of decitabine was tolerated without significant
toxicity.
3.4 Subgroup distribution and methylation levels
within the cohort
For 9/12 patients with ATRT and 3/10 non-ATRT tumors, full data
sets from 850k methylation profiling of the tumor prior to decitabine
therapywere gathered. Apart fromone case, all patientswere unequiv-
ocally allocated to one subgroup, as demonstrated in the tSNE plot in
Figure 3a. The average methylation level in tumors of patients with
a radiological response to therapy was higher than in nonresponding
patients (Figure 3b). With respect to subgroup, no significant corre-
lation could be detected in ATRTs, most likely owing to small sample
size and an overrepresentation of ATRT-SHH tumors (chi-square test
statistics 0.375). For two of the patients (patient 14 and patient 17,
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F IGURE 1 (a) Compound combinations. Decitabine was combined
with different conventional chemotherapeutics. VC(A), DOX, ICE, and
MTXwere administered according to recommendations of the
EU-RHAB registry, topotecan on an individual basis. VC(A), vincristine,
cyclophosphamide (actinomycin D); DOX, doxorubicin; ICE,
ifosfamide, carboplatinum, etoposide.; MTX, methotrexate. 1 One
patient received four courses of decitabine in combination with
intraventricular topotecan only; one patient was given a combination
of liposomal doxorubicin, melphalan, and decitabine. 2 Intraventricular
therapywas conducted in patients with central nervous system lesions
if no contraindications were present, either withmethotrexate or with
topotecan. (b) Standard treatment regimen. Patients received at least
two and up to five days of decitabine at the indicated doses. After
completion of the decitabine prephase, conventional chemotherapy
was started on the following day. Cycles restarted after day 21
both with ATRT-SHH) pre- and posttreatment samples were available.
Comparison of average methylation levels found a difference of 0.011
(patient 14) and 0.014 (patient 17), thus showing indeed a decrease in
overall methylation levels.
3.4.1 Case reports
Patient 7was diagnosedwith a nonmetastatic ATRT-SHH.He achieved
CR after resection, proton beam therapy, eight courses of conventional
chemotherapy, and HDCT. He remained in remission for eight months
until presenting with diffuse spinal dissemination, including two large
solid spinal lesions. A diagnostic biopsy was taken, and molecular
profiling through INFORM was initiated. Upon diagnosis of relapse,
conventional chemotherapy was restarted, supported by the use of
decitabine. At restaging following two decitabine-enhanced courses,
metastases demonstrated a definitive size reduction. After an addi-
tional course, treatment was stopped to proceed to radiotherapy and
the anticipated enrollment into a clinical trial (NCT02601937). A total
of fivemonths after start of decitabine andwhile on trial drug progress
was noted; the patient died after four months of palliative care.
Patient 10 presented with ATRT-SHH, inoperable at diagnosis due
to primary intracranial dissemination. He was treated with six courses
of conventional chemotherapy according to EU-RHAB; a partial resec-
tion of the primary tumor was undertaken. At restaging, further pro-
gression of several lesions was seen, and individual therapy with esca-
lation of conventional chemotherapy by adding decitabinewas started.
Regression of some solid lesions and meningeosis was seen after the
first courses, but other tumor manifestations progressed at the same
time. In palliative intention surgery and radiotherapywas administered
for local control and palliative chemotherapy with temozolomide was
initiated. The patient developed a secondary AML and succumbed
shortly thereafter due to progressive disease (no GLMdemonstrated).
Patient 16 experiencedmetastatic relapse to the lungs of a primarily
nonmetastasizedeMRTof the liver. CRhadpreviously beenmaintained
for 13 months after GTR, nine courses of conventional chemother-
apy, radiotherapy, and subsequent maintenance therapy. As salvage
treatment, metronomic chemotherapy (NCT01356290) was started,
but rapid progression was noted on imaging shortly thereafter. Due
to clinical deterioration, further treatment plans were terminated. The
patient nonetheless stabilized, and treatment including decitabinewas
restarted, leading to a major clinical improvement and size regression
of the pulmonary lesions. A total of four courses of decitabine were
administered until further progression was noted. Due to the overall
improved life expectancy, the patient was eligible for enrollment into
a clinical trial (NCT02601937), remaining progression free for another
eight weeks. The patient died of disease six months after the first dose
of decitabine.
4 DISCUSSION
To this day, diagnosis of RT is associated with a daunting prognosis.
Despite intensive multimodal approaches, many patients suffer from
early relapse or progression on therapy.11,23,30 Median OS in 99
patients from the EU-RHAB registry after relapse or progression
on therapy was 18 weeks, and only 20% were alive one year after
the event, emphasizing the desperate need for novel therapeutic
approaches (Steinbügl et al., unpublished). In vitro studies have
elucidated a multitude of affected pathways andmechanisms as a con-
sequence of SMARCB1 loss in RT, unveiling new potential therapeutic
targets. This includes among others the overexpression of Aurora
Kinase A,31,32 upregulation of EZH2,33 as well as CDK4/CDK6/cyclin
D1/RB pathway activation34,35 andmanymore.36
Translation of these findings into clinical trials has been challeng-
ing, mostly due to the low incidence and rapid course of disease. The
number of clinical trials specifically aimed at patients with relapsed
or refractory RT has been very limited, and clinical experiences have
scarcely been published. Wetmore et al. reported a case series of
four patients treated with the Aurora Kinase A inhibitor alisertib as
a single agent in relapsed or refractory ATRT, where all patients dis-
played disease stabilization and/or regression.37 A subsequent clin-
ical trial employing alisertib either as a single agent in relapsed or
refractory RT or in combination with conventional chemotherapy in
newly diagnosed RT is actively recruiting (NCT02114229). In a dif-
ferent trial, single-agent alisertib did not exhibit antitumor activity
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F IGURE 2 Exemplary imaging in a responder. MRI (axial T2with contrast) of patient #10 from 2months before initiation of decitabine therapy
and during first-line therapy, showing no cerebellar lesion (1); 3 weeks before initiation of decitabine therapy showing a newmetastasic lesion in
the cerebellum (2) and following 2 courses of decitabine plus conventional chemotherapy showing regression of the lesion (3). DAC, decitabine;
PD, progressive disease; MRI, magnetic resonance imaging
in four relapsed or refractory RT.38 Gotti et al. and Berland et al.
reported single cases of responses to metronomic chemotherapy
regimens in ATRT using either vinorelbine, cyclophosphamide, and
celecoxib or in the latter bevacizumab, liposomal cytarabine, cele-
coxib, cyclophosphamide, and etoposide.39,40 In a phase I trial of the
CDK4/6 inhibitor ribociclib, two of 15 patients with RT presented
with stable disease (SD). The trial enrolled 32 patients with neurob-
lastoma, RT, rhabdomyosarcoma, and anaplastic meningioma, and best
overall response was SD in nine patients.41 A phase I trial of the
EZH2 inhibitor tazemetostat in SMARCB1-deficient tumors is ongo-
ing (NCT02601937); responses have been reported in individual cases,
and further results are pending.42
We analyzed 22 patients, who had received decitabine for therapy
of tumor relapse or progression. To our knowledge, this is one of the
largest, for themost part uniformly treated, cohorts of relapsed or pro-
gressiveRT reported so far. Patientswith intra- and extracranial RThad
received a uniform first-line treatment according to EU-RHAB, min-
imizing the heterogeneity of the group. In this highly refractory set-
ting, a remarkable 27.3% demonstrated radiological signs of antitumor
activity following decitabine-augmented chemotherapy. We matched
this observation withmolecular data suggesting a correlation between
response status and methylation signature. Median OS and TTP were
prolonged in responders comparedwith non-responders, although not
significantly.
Our provocative results are clearly limited by the individual treat-
ment approaches outside of a clinical trial setting, the small cohort
size, and the retrospective nature of the data. Robust survival analysis
was accordingly limited. Furthermore, and as mentioned above, we
chose a very broad definition of response on imaging, as we interpret
size regression, however small, as a promising sign of antitumor
activity. Imaging was conducted in individual treatment settings
without standardized imaging protocols, precluding a systematic
assessment according to standardized and validated criteria such
as RANO or RECIST without having to exclude patients from this
valuable collection of cases. The main objective of this work was an
exploratory, clinical assessment of the potential biological activity of
the agent. Naturally this reduces the comparability to similar relapse
trials, as patients who were classified as responders may not have had
a response as defined by RANO or RECIST criteria. Any confirmatory,
prospective trials using decitabine will need to employ these validated
criteria or even iRECIST, because it is unclear whether the established
methods adequately assess novel therapeutic strategies, especially
immunotherapy.43–46
As the sample size was expectedly too small for convincing sta-
tistical evaluation, we included case reports to illustrate real-life
benefits after receiving decitabine-augmented salvage therapy. Case
10 explicitly demonstrates that primarily chemoresistant lesions were
responsive to therapy enhancement with decitabine, hinting at a
specific effect of the agent. Case reports 7 and 16 show that clinical
benefits may include bridging to local therapy measures and enroll-
ment into clinical trials as well as control of tumor-related symptoms.
Early-phase trials typically demand a minimum life expectancy for
enrollment; in case 16 this wasmade possible only through the tempo-
rary response seen after addition of decitabine to the therapy regimen.
Decitabine is an FDA- and EMA-approved agent, which has passed
multiple safety trials alone and in combination with chemotherapy
in children and adults.16,18,47,48 We also observed the frequently
described hematologic toxicity; however, no toxic death occurred and
only one patient was taken off medication due to side effects. In a
cohort of 143 ATRT patients treated with an unaltered EU-RHAB regi-
men, themajority of patients demonstrated grade3-4 hematologic tox-
icity, allowing the conclusion that adding decitabine did not lead to dis-
proportionate added toxicity.11
The rationale for the use of decitabine in RT is its potential for
demethylation. As proof of principle, we demonstrate that pre- and
posttreatment tumor samples in two patients did indeed have low-
ered methylation levels. Thus, we included methylation profiling data
andmethylation subgroup allocation into our analyses. Themajority of
ATRTs matched to the SHH subgroup. This is consistent with recently
published data demonstrating SHH as a negative predictive factor of
OS with an increased risk for metastatic disease, thus making these
patientsmore likely to fail first-line therapy.11,49 Comparison of overall
methylation levels suggests that differences in response to decitabine-
enhanced therapy might be influenced by tumor methylation levels.
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F IGURE 3 (a) Subgroup allocation. tSNE
plot of the samples for whichmethylation
profiling is available (n= 12). In this subcohort,
a total of seven patients were allocated to the
ATRT-SHH subgroup, one patient to
ATRT-MYC and for one patient, discrepant
subgrouping between two distinct tumor
samples revealed ATRT-TYR and ATRT-SHH.
The patients with non-ATRT tumors were
considered separately as subgroup “eMRT.” For
this image, only the primary tumors were
considered. Tumors that responded to therapy
are highlighted in green, nonresponding
patients in orange. As a reference cohort, 387
ATRT and eMRTwere derived fromHo et al.72
(b)Methylation levels. Indicates average
methylation levels per sample (y-axis). The
patients receiving decitabine have been
grouped into responders (n= 3) or
nonresponders (n= 8). As a reference, the
ATRT subgroups and the eMRT subgroup are
depicted as well
Consistently, future investigations should review methylation levels
as a potential marker for targeted therapy with demethylating agents
in RT.
In addition, it has been postulated that the overall antitumor
effect of decitabine is facilitated by resensitization of tumor cells
to chemotherapy, synergistic effects with platin-based agents, and
immunomodulation.50–67 Recent findings suggested high immuno-
genicity of RT.68,69 It seems logical that future clinical use of decitabine
should be in combination with immune-checkpoint inhibitors or other
agents targeting the immunogenicity of MRT; an early phase I trial has
already been rolled out.70 Other epigenetically active agents, such as
decitabine’s close structural analogue, azacytidine, should presumably
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be included in preclinical and clinical evaluation of the use of these
agents in RT.71
Despite the dismal prognosis of relapsed and refractoryMRT, there
is a lack of access to controlled clinical trials with innovative agents
targeting specific molecular characteristics. This has led to repeated
individual treatment attempts, using decitabine for enhancement of
conventional chemotherapy. In the current cohort, we detected indi-
cators of antitumor activity in a promising 27.3% of the cohort with-
out severe safety concerns. We propose that decitabine could benefit
patients with relapsed and refractoryMRT and should be included into
prospective clinical trials for these patients, preferably in a synergistic
combination with further targeted agents.
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